54468-86-9

Usage

Uses

Used in Pharmaceutical Industry:
2-amino-N,N-dimethylbenzenesulfonamide is used as an intermediate for the preparation of LDK378, a potent and selective anaplastic lymphoma kinase (ALK) inhibitor. This application is significant because LDK378 is designed to target and inhibit the activity of ALK, which is a key driver in certain types of cancer, such as non-small cell lung cancer (NSCLC) and anaplastic large cell lymphoma (ALCL). By inhibiting ALK, LDK378 can potentially slow down or stop the growth and progression of cancer cells that rely on this kinase for survival and proliferation.

Upstream product

• 23530-43-0 2-(N,N-dimethylaminosulfonyl)nitrobenzene 

Downstream Products

• 501102-68-7 NSC₃₀₉₉₇₁ 

Relevant academic research and scientific papers

AXL INHIBITOR FORMULATIONS

Formulations of Compound 1 or a pharmaceutically acceptable salt thereof are described. Also disclosed are capsules having a dry blended powder comprising Compound 1 or a pharmaceutically acceptable salt thereof. The Compound 1 or a pharmaceutically accep

AXL KINASE INHIBITORS AND USE OF THE SAME

Tartrate salts of the compound of structure (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrat

Compound used as ALK (anaplastic lymphoma kinase) inhibitor and application thereof

The invention discloses a compound shown in a formula I, and pharmaceutically acceptable salts, stereoisomers, solvates or predrugs. The symptoms are defined in claim requirements. The compound shownin the formula I has good inhibiting activity on ALK (anaplastic lymphoma kinase), and can be used for preparing medicines for adjusting the activity of the ALK activity or treating the ALK-related diseases, especially nonsmall-cell lung cancer drugs. (The formula I is shown in the attached figure.).

POLYCYCLIC ANAPLASTIC LYMPHOMA KINASE INHIBITOR

Provided is a polycyclic inhibitor of anaplastic lymphoma kinase as represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1, R2, R3, R4, and ring A are as defined in the description. The invention also relates to a method for preparing the compound, a pharmaceutical preparation and a pharmaceutical composition comprising the compound, and use of the compound, the pharmaceutically acceptable salt or stereoisomer thereof in manufacture of a medicament for the treatment and/or prevention of an anaplastic lymphoma kinase-mediated cancer or non-cancer related diseases.

Of tetracyclic Anaplastic lymphoma kinase inhibitors (by machine translation)

The invention belongs to the field of medical technology, in particular to general formula (I) as shown in of tetracyclic Anaplastic lymphoma kinase inhibitor, its pharmaceutically acceptable salt or a stereoisomer thereof, wherein R 1, R 2, R 3, R 4, R 5 and A link like defined in the specification. The invention also relates to methods of preparing such compounds, pharmaceutical preparations comprising these compounds and pharmaceutical composition, the compound and, its pharmaceutically acceptable salts or stereoisomers thereof, in the preparation of the treatment and/or prevention of Anaplastic lymphoma kinase-mediated cancer diseases related to the application of the medicament. (by machine translation)

COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS

Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes.

PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided compounds of formula (I), wherein R1, R2, X1, X2 and n have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.

ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS

The present invention relates to compounds of Formula (I) and salts solvates and hydrates thereof. The invention further relates to pharmaceutical compositions containing said compounds and methods of treating neurological and neuropsychistric disorders using said compounds.

Azo coupling of o- and p-(dialkylaminosulfonyl)benzene-diazonium salts with 7-acetylamino-4-hydroxynaphthalene-2-sulfonic acid in citrate-phosphate buffer solution

Dependences of the partial rate constants for azo coupling of o-(dialkylaminosulfonyl)benzene-diazonium salts with 7-acetylamino-4-hydroxynaphthalene-2-sulfonic acid (N-Acetyl-I-acid) on the fraction of the dianionic form of the latter indicate considerable steric hindrances to the second stage of the reaction. Ionization of the hydroxy group of N-acetyl-I-acid gives rise to additional electrostatic repulsion at the stage of formation of the σ complex, which reduces the rate of azo coupling at the 3-position of orthanilic acid.